Latner Thoracic Surgery Research Laboratories, University Health Network, University of Toronto, Toronto, Ontario, Canada.
Latner Thoracic Surgery Research Laboratories, University Health Network, University of Toronto, Toronto, Ontario, Canada; Department of Thoracic Surgery, University of Tokyo, Tokyo, Japan.
J Thorac Cardiovasc Surg. 2018 Sep;156(3):1305-1315. doi: 10.1016/j.jtcvs.2018.05.003. Epub 2018 May 29.
Our objective was to develop a rapid-onset and durable gene-delivery strategy that is applicable at the time of transplant to determine its effects on both acute rejection and chronic lung allograft fibrosis using a mouse orthotopic lung transplant model.
C57BL/6 mice received an orthotopic left lung transplant from syngeneic donors or C57BL/10 donors. By using syngeneic lung transplantation, we established a novel gene transfer protocol with lentivirus luciferase intrabronchial administration to the donor lung ex vivo before transplantation. This strategy was applied in allogeneic lung transplantation with lentivirus engineering expression of human interleukin-10 or lentivirus luciferase (control).
Bioluminescent imaging revealed that the highest early transgene expression was achieved when lentivirus luciferase was administered both directly into the donor lung graft ex vivo before implantation and subsequently to the recipient in vivo daily on post-transplant days 1 to 4, compared with post-transplant in vivo administration only (days 0 to 4). Our previous work with adenoviral interleukin-10 gene therapy indicates that early interleukin-10 expression in the allograft is desirable. Therefore, we selected the combined protocol for human interleukin-10 encoding lentiviral vector therapy. In the allogeneic transplant setting, ex vivo and in vivo human interleukin-10 encoding lentiviral vector therapy reduced acute rejection grade (2.0 vs 3.0, P < .05) at day 28. The percentage of fibrotic obliterated airways was reduced in the human interleukin-10 encoding lentiviral vector-treated group (10.9% ± 7.7% vs 40.9% ± 9.3%, P < .05).
Delivery of lentiviral interleukin-10 gene therapy, using a novel combined ex vivo and in vivo delivery strategy, significantly improves acute and chronic rejection in the mouse lung transplant model.
我们旨在开发一种快速起效且持久的基因传递策略,使其可在移植时应用,通过建立小鼠原位肺移植模型,观察其对急性排斥反应和慢性肺移植物纤维化的影响。
C57BL/6 小鼠接受同基因供体或 C57BL/10 供体的原位左肺移植。通过使用同基因肺移植,我们建立了一种新的基因转移方案,即通过支气管内给予慢病毒荧光素酶,对供体肺进行离体预处理,然后在移植后第 1 至 4 天对受体进行体内给药。该策略应用于慢病毒工程表达人白细胞介素 10 或慢病毒荧光素酶(对照)的同种异体肺移植。
生物发光成像显示,与仅在移植后第 0 至 4 天进行体内给药相比,在移植前直接将慢病毒荧光素酶注入供体肺移植物中,然后在移植后第 1 至 4 天每天对受体进行体内给药,可获得最高的早期转基因表达。我们之前使用腺病毒白细胞介素 10 基因治疗的研究表明,同种异体移植物中早期白细胞介素 10 的表达是理想的。因此,我们选择了联合方案进行慢病毒载体编码人白细胞介素 10 治疗。在同种异体移植中,离体和体内慢病毒载体编码人白细胞介素 10 治疗可降低第 28 天的急性排斥反应等级(2.0 比 3.0,P <.05)。在慢病毒载体编码人白细胞介素 10 治疗组中,纤维化闭塞气道的百分比降低(10.9%±7.7%比 40.9%±9.3%,P <.05)。
使用新型的离体和体内联合传递策略,传递慢病毒白细胞介素 10 基因治疗可显著改善小鼠肺移植模型中的急性和慢性排斥反应。